Treatment & Guidelines
The rate of death from any cause or disabling stroke was similar in the TAVI group and the sAVR group (p=0.001 for noninferiority). At 2 years, the event rates were 19.3% in the TAVI group and 21.1% in the sAVR group (p=0.25)1
All percentages are Kaplan–Meier estimates at the specific time point and thus do not equal the number of patients divided by the total number of patients in the treatment group. P-values are for point-in-time comparisons.
Patients receiving transfemoral TAVI enjoyed an improved health status through 2 years of follow-up after the procedure from baseline, as measured using the KCCQ-OS (Kansas City Cardiomyopathy Questionnaire – Overall Summary)2
TAVI has demonstrated similar efficacy in intermediate-risk patients to clinical trials3,4
Content relating to Tavi.today is intented for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.